A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- CHU Toulouse
-
Creteil, France, 94010
- Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny
-
Dijon, France, 21034
- Hôpital du Bocage
-
Le Mans, France, 72037
- Centre Hospitalier Le Mans
-
Le Mans, France, 72015
- Centre Jean Bernard
-
Lille, France, 59037
- CHRU de Lille - Hopital Claude Huriez
-
Montpellier, France, 34295
- CHU Montpellier - Saint ELOI
-
Nantes, France, 44093
- CHU - Hôtel Dieu hematolgie clinique
-
Pierre Benite, France, 69495
- Centre Hospitalier Lyon Sud; Hematolgie
-
Rennes, France, 35033
- CHU de Rennes - Hopital de Pontchaillo
-
Rouen, France, 76038
- Centre Henri Becquerel
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Florida
-
Miami, Florida, United States, 33136
- University Miami
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Norton Medical Plaza II
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center; Hematology/Oncology
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator
- Histologically documented CD20-positive lymphoma as determined by the local laboratory
- Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)
- At least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by CT scan or magnetic resonance imaging [MRI])
- Availability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL
- Agreement to comply with all local requirements of the lenalidomide risk minimization plan
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period (including periods of treatment interruption), and for at least 18 months after the last dose of study treatment
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm for at least 3 months after the last dose of study treatment
Exclusion Criteria:
- Grade 3b follicular lymphoma
- History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)
- Known CD20-negative status at relapse or progression
- Central nervous system lymphoma or leptomeningeal infiltration
- Prior allogeneic stem-cell transplantation (SCT)
- Completion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1
- Prior standard or investigational anti-cancer therapy as specified in protocol
- History of resistance to lenalidomide or response duration of <1 year
- Treatment with systemic immunosuppressive medications
- History of solid organ transplantation
- Clinically significant toxicity from prior therapy that has not resolved to Grade <=2 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], v4.0) prior to Day 1 of Cycle 1
- History of erythema multiforme, Grade >= 3 rash, or blistering following prior treatment with immunomodulatory derivatives such as thalidomide and lenalidomide
- Active bacterial, viral, fungal, or other infection
- Positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody at screening
- Known history of HIV positive status
- History of progressive multifocal leukoencephalopathy
- History of autoimmune disease
- Contraindication to treatment for TE prophylaxis
- Grade <= 2 neuropathy
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Evidence of any significant, uncontrolled concomitant disease
- Inadequate hematologic function (unless due to underlying lymphoma)
- Abnormal laboratory values (unless due to underlying lymphoma)
- Pregnant or lactating or intending to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Atezolizumab-G-lena 15mg
Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
|
Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment.
Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment.
During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
|
|
Experimental: Atezolizumab-G-lena 20mg
Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
|
Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment.
Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment.
During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria
Time Frame: 6 months (up to clinical cut-off date (CCOD) of 23 October 2018)
|
Complete response (CR) was evaluated through use of PET-CT scans, using the Modified Lugano 2014 criteria.
Response was determined by the IRC.
|
6 months (up to clinical cut-off date (CCOD) of 23 October 2018)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving CR at EOI, as Determined by the Investigator Using Modified Lugano 2014 Criteria
Time Frame: 6 months (up to CCOD of 23 October 2018)
|
CR was evaluated through use of PET-CT scans, using the Modified Lugano 2014 criteria.
Response was determined by the Investigator.
|
6 months (up to CCOD of 23 October 2018)
|
|
Percentage of Participants Achieving CR at EOI, as Determined by the IRC and Investigator Using Lugano 2014 Criteria
Time Frame: 6 months (up to CCOD of 23 October 2018)
|
CR was evaluated through use of CT scans, using the Lugano 2014 criteria.
Response was determined by the IRC and by the Investigator.
|
6 months (up to CCOD of 23 October 2018)
|
|
Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of PET-CT Scans
Time Frame: 6 months (up to CCOD of 23 October 2018)
|
Objective response was evaluated through use of PET-CT scans, using the Lugano 2014 or modified Lugano 2014 criteria.
Response was determined by the IRC and by the Investigator.
|
6 months (up to CCOD of 23 October 2018)
|
|
Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of CT Scans Alone
Time Frame: 6 months (up to CCOD of 23 October 2018)
|
Objective response was evaluated through use of CT scans alone, using the Lugano 2014.
Response was determined by the IRC and by the Investigator.
|
6 months (up to CCOD of 23 October 2018)
|
|
Percentage of Participants With Best Response (CR or PR) During the Study as Determined by the Investigator on the Basis of CT Scans Alone
Time Frame: 30 months
|
Best Response was evaluated through use of CT scans alone, using the Lugano 2014.
Response was determined by the Investigator.
|
30 months
|
|
Percentage of Participants With Adverse Events and Serious Adverse Events
Time Frame: Baseline up to approximately 59 months
|
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as adverse events.
|
Baseline up to approximately 59 months
|
|
Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 2 of Study Treatment
Time Frame: Day 1 - Day 28 of second cycle
|
Does limiting toxicity (DLT) is defined as any one of the following events occurring during Cycle 2 of treatment and assessed by the investigator as related to study treatment: - Adverse event of any grade that leads to a delay of more than 14 days at the start of the next treatment cycle; - Hematologic adverse events (neutropenia, thrombocytopenia); - Non-hematologic adverse event, except IRRs, diarrhea, nausea or vomiting
|
Day 1 - Day 28 of second cycle
|
|
Serum Concentration of Obinutuzumab (mcg/mL)
Time Frame: Baseline up to approximately 59 months
|
The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year
|
Baseline up to approximately 59 months
|
|
Serum Concentration of Atezolizumab (mcg/mL)
Time Frame: Baseline up to approximately 59 months
|
The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year
|
Baseline up to approximately 59 months
|
|
Serum Concentration of Lenalidomide (ng/mL)
Time Frame: Baseline up to approximately 59 months
|
The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; HR = Hour
|
Baseline up to approximately 59 months
|
|
Number of Participants Positive for Human Anti-human Antibodies (HAHA) to Obinutuzumab
Time Frame: Baseline up to approximately 59 months
|
The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year.
All baseline and post-baseline samples from participants were negative for HAHAs to obinutuzumab and the results are shown below.
|
Baseline up to approximately 59 months
|
|
Number of Participants Positive for Anti-therapeutic Antibodies (ATAs) to Atezolizumab
Time Frame: Baseline up to approximately 59 months
|
The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year.
All baseline and post-baseline samples were negative for ATAs to atezolizumab and the results are shown below.
|
Baseline up to approximately 59 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Follicular
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Obinutuzumab
- Atezolizumab
Other Study ID Numbers
Other Study ID Numbers
- BO29562
- 2015-002467-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.